Milton M. Hom, OD, FAAO, FACAAI (Sc)

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.

Considering safety and efficacy of new drops and the potential impact on your patients.

A panel of ophthalmologists and optometrists conclude a discussion about dry eye disease by commenting on advances occurring in the field and future expectations for managing patients.

Unique clinical trials and novel products of interest currently under investigation for the treatment of dry eye disease.

Strategies that can help eye care specialists work with patients to establish and stick to treatment plans for dry eye disease.

Types of in-office procedures currently being used by ophthalmologists and optometrists to aid in the treatment of dry eye disease.

Eye care specialists describe when corticosteroid therapy should be considered to treat dry eye disease and describe best practices when treating pre-surgical patients.

The most common types of artificial tears recommended to help manage dry eye disease and the importance of proper use for full benefit.

Eye care professionals discuss their comfort in recommending oral omega-3 fatty acids to help treat dry eye disease.

How to select and discuss sequential therapy with patients who have dry eye disease and set expectations for treatment.

Resources and strategies that can be used to help educate patients about dry eye disease and optimize adherence to therapy.

Criteria that would prompt further evaluation for dry eye disease and the types of tests used to work-up and accurately diagnose the condition.

Eye care professionals explain the impact of unstable tear film and untreated dry eye disease on patient quality of life.

The impact of autoimmune and systemic diseases as well as environmental triggers on the development of dry eye disease.

A panel of ophthalmologists and optometrists begin a discussion on the management of dry eye disease by defining the condition and highlighting common symptoms.

An FDA-approved drop would be a game changer in the treatment of Demodex blepharitis

Years ago, Mark Dunbar, OD, FAAO, of Bascom Palmer shared with me some cases about rosacea. I was a little taken aback because the cases he shared concerned Hispanic patients, not the usual patients of Northern English isles descent we read about in school. The skeptic in me was doubtful, even though Mark had great pictures and detailed data from the cases.